EUR 16.55 at Lang & Schwarz: TAK stock pre-market unchanged versus the prior close
Published on 10/08/2026 at 07:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
TAK stock was unchanged at EUR 16.55 in pre-market trading at Lang & Schwarz at 7:48 a.m. CEST on October 8, 2026, versus the prior close of EUR 16.55 from October 7, 2026.
Pre-market trading
The Lang & Schwarz quote showed a bid of EUR 16.00 and an ask of EUR 17.10. The pre-market indication was recorded before the Xetra session, which begins at 9:00 a.m. CEST. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of TAK stock.
Earlier regulatory development
In a September 14, 2026 release, Takeda Pharmaceutical Company Limited said the U.S. Food and Drug Administration had accepted its New Drug Application for zasocitinib, also known as TAK-279, under Priority Review for adults with moderate-to-severe plaque psoriasis. Business Wire reported that the submission was supported by Phase 3 studies involving nearly 3,000 patients. The release said the FDA decision was anticipated in the first quarter of 2027 and that the European Medicines Agency had also accepted Takeda’s marketing authorization application for the treatment.
